Stock Details
BMY is Bristol-Myers Squibb Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 76.17$. Average daily volumn in 3 months 14.67M. Market cap 163.60B

Stock symbol : BMY. Exchange : NYSE. Currency : USD
Lastest price : 76.84$. Total volume : 10.88M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Bristol-Myers Squibb Company (BMY)
Last Price

Previous Close77.00
Day Range75.77-76.98
Bid76.31 x 800
Ask77.86 x 900
Average Volume14.67M
Market Cap163.6B
52 Week Range53.22-80.59
Trailing P/E27.25
Foward P/E9.50
Dividend (Yield %)2.81%
Ex-Dividend Date2022-06-30

Financial Details

According to Bristol-Myers Squibb Company's financial reports the company's revenue in 2021 were 46.38B an increase( +9.52%) over the years 2020 revenue that were of 42.52B. In 2021 the company's total earnings were 6.99B while total earnings in 2020 were -9.02B(-166.67%).

Loading ...


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indi... cations; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Market Cap:
Total Assets:
Total Cash:

News about "Bristol-Myers Squibb Company"


Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Great Valley Advisor Group Inc.

Source from : Defense World - 11 hours ago

Great Valley Advisor Group Inc. grew its position in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 7.5% during the first quarter, according to its most recent Form 13F filing with the ...See details»


Bristol-Myers Squibb: When Will The Correction End?

Source from : Seeking Alpha - 3 days ago

Bristol-Myers Squibb's EBITDA margin is 47.2% at the end of Q1, one of the largest in the pharmaceutical industry. Find out when the correction might end.See details»


Bristol-Myers Squibb Company (NYSE:BMY) Stock Goes Ex-Dividend In Just Two Days

Source from : YAHOO!Finance - 5 days ago

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Bristol-Myers Squibb Company (NYSE:BMY) is about to trade ex-dividend in the next two days.See details»


Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Creative Financial Designs Inc. ADV

Source from : Defense World - 2 days ago

Creative Financial Designs Inc. ADV trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 90.6% in the first quarter, according to its most recent 13F filing with the ...See details»


Bristol-Myers Squibb: Annual Mid Single-Digit Growth Equals Incremental Upside

Source from : Seeking Alpha - 4 days ago

BMY shares were stagnant for nearly 5 years before gaining ~30% across the past 6 months. Read more to find out why BMY shares remain good value.See details»


Why is Bristol-Myers Squibb Company (BMY) up 10.98% from the day 1 this year?

Source from : investchronicle - 11 days ago

At the end of the latest market close, Bristol-Myers Squibb Company (BMY) was valued at $72.62. In that particular session, Stock kicked-off at the price of $72.71 while reaching the peak value of $74 ...See details»

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Source from : YAHOO!Finance - 3 days ago

Bristol Myers Squibb (BMY) closed the most recent trading day at $78.28, moving -0.53% from the previous trading session.See details»

Bristol-Myers Squibb Company (NYSE:BMY) Slides -0.22 Percent In Recent Trade, What Can We Expect Next?

Source from : stocksregister - 3 days ago

Bristol-Myers Squibb Company (NYSE:BMY) traded at $78.53 at last check on Wednesday, June 29, made a downward move of -0.22% on its previous day’s price. Looking at the stock we see that its previous ...See details»


Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Source from : Yahoo Finance - 1 days ago

Bristol Myers Squibb (BMY) closed the most recent trading day at $76.84, moving -0.21% from the previous trading session.See details»

Looking Into Bristol-Myers Squibb's Recent Short Interest

Source from : - 3 days ago

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has risen 4.49% since its last report. The company recently reported that it has 34.46 million shares sold short, which is 1.63% of all regular ...See details»


Here's How to Treat Bristol-Myers Squibb's Charts

Source from : - 5 days ago

Pharmaceutical giant Bristol-Myers Squibb (BMY) has broken out to a new high for the move up. Traders should be long from our March 7 review, where we wrote that "Traders could go long BMY at current ...See details»


Bristol Myers must face $6.4 bln lawsuit over delayed cancer drug

Source from : Reuters - 7 days ago

A U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co of delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, ...See details»

Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company

Source from : MarketWatch - 29 days ago

Bristol Myers Squibb expects to finance the acquisition with cash on hand. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs ...See details»


Ex-Dividend Reminder: Choice Hotels International, Sysco and Bristol Myers Squibb

Source from : Nasdaq - 4 days ago

Looking at the universe of stocks we cover at Dividend Channel, on 6/30/22, Choice Hotels International, Inc. (Symbol: CHH), Sysco Corp (Symbol: SYY), and Bristol Myers Squibb Co. (Symbol: BMY) will ...See details»